Clinical Trial Detail

NCT ID NCT02178722
Title A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Incyte Corporation
Indications

melanoma

endometrial adenocarcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

renal cell carcinoma

non-small cell lung carcinoma

urethra transitional cell carcinoma

Her2-receptor negative breast cancer

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Epacadostat

Age Groups: adult

Additional content available in CKB BOOST